Brief: Canariabio Achieves Significant Milestone With FDA's Orphan Drug Designation For Mab-Ar20.5 Targeting Pancreatic Cancer
21/08/2023 13:21
Aug 21 (Reuters) -
* CANARIABIO ACHIEVES SIGNIFICANT MILESTONE WITH FDA'S
ORPHAN DRUG
DESIGNATION FOR MAB-AR20.5 TARGETING PANCREATIC CANCER
* CANARIABIO INC - PLANNING TO INITIATE CLINICAL TRIALS TO
ASSESS
SAFETY AND EFFICACY OF MAB-AR20.5 IN PATIENTS WITH PANCREATIC
CANCER
Source text for Eikon: ID:nPn7rxgBla
Further company coverage: 016790.KQ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hyundai Feed
See all newsBrief: CanariaBio Inc Announces Enrollment Completion of randomized Phase 2 study of Oregovomab in combination with chemotherapy as neo-adjuvant treatment of patients with Advanced Ovarian Cancer
Brief: Canariabio Achieves Significant Milestone With FDA's Orphan Drug Designation For Mab-Ar20.5 Targeting Pancreatic Cancer